« Back to Medicines list

Micardis 20 mg Tablets

  • Name:

    Micardis 20 mg Tablets

  • Company:
    info
  • Active Ingredients:

    Telmisartan

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/06/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 17/11/2017
print

Print ViewKeyword Search SmPC

Boehringer Ingelheim Limited

Boehringer Ingelheim Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Actilyse Active Ingredients Alteplase
Medicine Name Actilyse Cathflo 2 mg Active Ingredients Alteplase
Medicine Name APTIVUS 100 mg/ml oral solution Active Ingredients Tipranavir
Medicine Name Aptivus 250 mg soft capsules Active Ingredients Tipranavir
Medicine Name Atrovent 250 UDVs, 250 micrograms/1ml Nebuliser Solution Active Ingredients ipratropium bromide monohydrate
Medicine Name Atrovent 500 UDVs, 500 micrograms/2ml Nebuliser Solution Active Ingredients ipratropium bromide monohydrate
Medicine Name Atrovent Inhaler CFC-Free Active Ingredients ipratropium bromide monohydrate
Medicine Name Catapres Ampoules Active Ingredients Clonidine hydrochloride
Medicine Name Catapres Tablets 100 micrograms Active Ingredients Clonidine hydrochloride
Medicine Name Giotrif 20 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 30 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 40 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 50 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Glyxambi 10 mg/5 mg film-coated tablets Active Ingredients Empagliflozin, Linagliptin
Medicine Name Glyxambi 25 mg/5 mg film-coated tablets Active Ingredients Empagliflozin, Linagliptin
Medicine Name Jardiance 10 mg and 25 mg Film-Coated Tablets Active Ingredients Empagliflozin
Medicine Name Jentadueto 2.5 mg/850 mg film-coated tablets and Jentadueto 2.5 mg/1,000 mg film-coated tablets Active Ingredients Linagliptin, Metformin Hydrochloride
Medicine Name Metalyse 10,000 units Active Ingredients Tenecteplase
Medicine Name Micardis 20 mg Tablets Active Ingredients Telmisartan
Medicine Name Micardis 40 mg Tablets Active Ingredients Telmisartan
Medicine Name Micardis 80 mg Tablets Active Ingredients Telmisartan
Medicine Name MicardisPlus 40 mg/12.5 mg tablets Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name MicardisPlus 80 mg/12.5 mg tablets Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name MicardisPlus 80 mg/25 mg Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name Mirapexin prolonged-release tablets Active Ingredients Pramipexole dihydrochloride monohydrate
1 - 0 of 47 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 June 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to MA holder contact details

Updated on 5 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 January 2018 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 21 November 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Change to MA holder contact details
  • Correction of spelling/typing errors
  • Improved presentation of PIL

Updated on 17 November 2017 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The following sections of the SPC have been updated to combine the SPCs and align with the current European Template 1, 2, 3, 4.2, 4.5, 4.8, 4.9, 5.2, 6.3, 6.5, 6.6, 8 and 10. A minor editorial correction has also been made to section 4.4.

Section 10, date of revision of the text has also been updated.

Updated on 17 November 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 27 January 2015 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 26 September 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to drug interactions
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 24 September 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The SPCs have been updated to been revised to take into account the updated wording for concomitant use with ARBs or aliskiren in the contraindication, warning and interactions section of SPC following conclusion of the EU Art 31 Referral Procedure on RAS acting agents – class labelling request (ref EMEA-H-A-31-1370).  Date of EC decision is 4 September 2014 with final text being available 10 September. Sections affected are 4.2, 4.3, 4.4, 4.5 also with revision to 5.1. In addition, in section 4.8 the Irish Authority contact details for Adverse Event reporting have been revised following the recent authority name change. Date of revision has also been updated to September 2014.

Updated on 27 January 2014 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 27 January 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

Dysgeusia has been added to the tabulated summary of adverse reactions (in the Gastrointestinal disorders details) of this section.

 

New text regarding the reporting of suspected adverse reactions in the UK, Ireland and Malta has been added at the end of this section.  In total, four new paragraphs have been added.

 

Section 10 Date of Revision of the Text

The date has been amended from May 2013 to December 2013.

 

Updated on 18 October 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 20 June 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to storage instructions
  • Change to drug interactions
  • Change to date of revision
  • Change to MA holder contact details

Updated on 20 June 2013 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 1; 2; 3; 6.3; 6.5; 8 updates due to splitting into separate documents relating to different strengths

Section 4.4 has been updated with a warning statement that concomitant use of Telmisartan with aliskiren is contraindicated in patients with diabetes or renal impairment under the subheading ‘Dual blockade of the Renin-Angiotensin-Aldosterone System’.

Sections 4.2, 4.3 and 4.5
Related statements to that in section 4.4 have also been included.

Section 4.5
Also includes new information on co-administration of telmisartan with digoxin.

Sections 5.1, 5.2 and 5.3
Minor/editorial updates have been made.

Section 10
Date of revision of the text has also been updated to May 2013.

Updated on 12 March 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 6 July 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about driving or using machinery
  • Change to how the medicine works
  • Change to further information section
  • Change to date of revision

Updated on 19 July 2011 PIL

Reasons for updating

  • Change to name of manufacturer
  • Change to MA holder contact details

Updated on 6 June 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Introduction of new pack/pack size

Updated on 23 December 2009 PIL

Reasons for updating

  • Change to, or new use for medicine

Updated on 9 October 2009 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 16 June 2009 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 11 September 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 12 September 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 13 June 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 23 May 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 17 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie